{
    "filename": "acsinfecdis.0c00052.pdf",
    "content_type": "text/html",
    "file_size": 0,
    "metadata": {
        "identifiers": {
            "doi": "10.1021/acsinfecdis.0c00052",
            "url": "https://dx.doi.org/10.1021/acsinfecdis.0c00052"
        },
        "doi": "10.1021/acsinfecdis.0c00052",
        "author": "Jimin Xu, Pei-Yong Shi, Hongmin Li, Jia Zhou",
        "title": "Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential",
        "date": 2020,
        "affiliations": [
            "Wadsworth Center, New York State Department of Health, 120 New Scotland Avenue, Albany, New York 12208, United States"
        ],
        "journal": "ACS Infectious Diseases",
        "abstract": "The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics. Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, ZIKV, HCV, and human adenovirus, indicating its potential as an antiviral agent. In this brief review, we summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19.",
        "references": "",
        "references_ris": "",
        "links": [],
        "author_conclusions": [],
        "table_captions": [],
        "figure_captions": []
    },
    "sections": {
        "introduction": [
            "The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics. Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, ZIKV, HCV, and human adenovirus, indicating its potential as an antiviral agent. In this brief review, we summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19."
        ]
    },
    "structured_content": {
        "Abstract": [
            "The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics. Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, ZIKV, HCV, and human adenovirus, indicating its potential as an antiviral agent. In this brief review, we summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19."
        ]
    },
    "participants": [],
    "statistics": [],
    "keywords": [
        "coronavirus disease",
        "sars cov",
        "brief review",
        "potential clinical use",
        "viral infection",
        "broad antiviral activity",
        "recent outbreak",
        "human adenovirus",
        "niclosamide",
        "micromolar potency",
        "urgent need",
        "mers cov",
        "broad spectrum antiviral agent niclosamide",
        "anthelminthic drug",
        "COVID-19"
    ],
    "keyword_relevance": {
        "niclosamide": 0.14285714285714285,
        "COVID-19": 0.14285714285714285,
        "coronavirus disease": 0.07142857142857142,
        "brief review": 0.07142857142857142,
        "potential clinical use": 0.07142857142857142,
        "viral infection": 0.07142857142857142,
        "broad antiviral activity": 0.07142857142857142,
        "recent outbreak": 0.07142857142857142,
        "human adenovirus": 0.07142857142857142,
        "micromolar potency": 0.07142857142857142,
        "urgent need": 0.07142857142857142,
        "anthelminthic drug": 0.07142857142857142,
        "sars cov": 0.0,
        "mers cov": 0.0,
        "broad spectrum antiviral agent niclosamide": 0.0
    },
    "species": [],
    "summary": [
        "The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics.",
        "Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 across all institutions and individuals.",
        "These metrics are regularly updated to reflect usage leading up to the last few days.",
        "The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online.",
        "Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article.",
        "Find more information on the Altmetric Attention Score and how the score is calculated.",
        "Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, ZIKV, HCV, and human adenovirus, indicating its potential as an antiviral agent.",
        "The authors summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19."
    ],
    "structured_summary": {
        "Introduction": [
            "The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics.",
            "Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 across all institutions and individuals."
        ],
        "Results": [
            "These metrics are regularly updated to reflect usage leading up to the last few days.",
            "The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online.",
            "Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article.",
            "Find more information on the Altmetric Attention Score and how the score is calculated."
        ],
        "Conclusion": [
            "Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, ZIKV, HCV, and human adenovirus, indicating its potential as an antiviral agent.",
            "The authors summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19."
        ]
    },
    "reference_links": [],
    "facts": [
        "The recent outbreak of coronavirus disease 2019 highlights an urgent need for therapeutics",
        "Article Views are the COUNTER-compliant sum of full text article downloads since November 2008",
        "The Altmetric Attention Score is a quantitative measure of the attention"
    ],
    "claims": [
        "In this brief review, we summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19"
    ],
    "findings": [],
    "processes": [],
    "key_statements": [
        "We summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19"
    ],
    "top_statements": [
        "The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics",
        "We summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19"
    ],
    "headline": "We summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19",
    "contexts": [],
    "abbreviations": {}
}
